- Agriculture
- Antibiotic/anti-viral
- Biologics
- Biomarkers ×
-
By Clinical Application
- Anesthesiology
- Blood & Lymphatic Disease
- CNS & Neurosciences
- Dermatology
- Diabetes, Metabolism, Endocrinology & Obesity
- Ear, Nose, & Throat
- Emergency Services
- Gastroenterology & Digestive Disease
- General & Plastic Surgery
- Health Education, Medical Training and Operations
- Heart and Vascular
- Immunology, Autoimmune & Inflammation
- Infectious Diseases
- Mental Health
- Multiple clinical applications
- Musculoskeletal Disorders, Orthopedics/Bone
- Nephrology/Renal
- Oncology x
- Ophthalmology
- Orphan Diseases
- Pediatrics
- Physical Medicine & Rehabilitation
- Radiology
- Regenerative Medicine / Tissue Engineering
- Reproductive Health: Obstetrics & Gynecology
- Respiratory & Pulmonary
- Surgery
- Transplantation
- Urology
- Wound Healing
- COVID-19
- Creative Works
- Diagnostics
- Drug Delivery
- Drug screening and discovery
- Energy, Cleantech & Environmental
- Engineering & Physical Sciences
- Gene therapy
- Imaging
- Materials
- Medical Devices
- Nutraceuticals
- Other
- Research & Design Tools
- RNAi/siRNA
- Sensors & Controls
- Small molecules
- Software & Information Technology
- Stem Cells
- Vaccines
- Veterinary Medicine
New small molecules targeting castration-resistant prostate cancer
Unmet Need Prostate cancer (PC) is the second most common male cancer globally and represents 15% of all cancers diagnosed in males. An estimated 34,700 deaths were predicted to occur from PC in the U.S.…
Olfactory neuroblastoma mouse model
Unmet Need Olfactory neuroblasoma (ONB) is an agressive tumor that is thought to arise in basal stem cells in the adult olfactory epithelium. This rare cancer affects 1 in 2.5 million people each year with…
Method to overcome treatment resistant cancer by rescuing STING signaling
Unmet Need Among types of brain cancer, glioblastoma (GBM) is the most common and the most devastating. Over 8000 patients are diagnosed annually in the United States, accounting for half of all primary malignant brain…
Breast cancer risk prediction technology using genomic classifier
Unmet Need The earliest form of breast cancer, ductal carcinoma in situ (DCIS), is diagnosed in almost 50,000 people in the U.S. each year. DCIS is considered noninvasive, as abnormal cells have not spread out…
A genomics-based method to identify cancer patients that will benefit from immune checkpoint therapy
Unmet Need Non-small-cell lung cancer accounts for 82% of all lung cancer diagnoses. Immune checkpoint blockade treatment is an exciting new course of action among advanced stage non-small-cell lung cancer patients. However, only a minority…
Genomic Biomarkers of Locally Advanced Breast Cancer (LABC) and Inflammatory Breast Cancer (IBC)
Unmet Need Locally advanced breast cancer (LABC) and inflammatory breast cancer (IBC) are associated with high 5-year mortality rates (respectively 55% and 33%), especially when compared to early-stage breast cancers (~80%). LABC and IBC are…
A method of identifying a B cell malignancy as Hodgkin’s Lymphoma
Unmet Need Malignancies derived from mature B cells are common and constitute the majority of blood cancers. The biology of these leukemias and lymphomas reflect defined stages of normal B-cell differentiation. Correct diagnosis of B…
Predicting immune checkpoint therapy for breast cancer patients using LRRK2 mutations
Unmet Need The treatment of various cancers has been revolutionized by the development of effective immunotherapies that are now established as powerful clinical tools. Unfortunately, it is also now well documented that only a minority…
A method of determining resistance of a blood cancer to PI3K inhibitors as well as treating blood cancers
Unmet Need Lymphomas are highly diverse and among the most common cancers in the US; approximately 1 in 50 Americans will be diagnosed with a lymphoma in their lifetime. Standard therapy for lymphomas generally includes…
Biomarkers for high-grade serous ovarian carcinomas
Unmet Need The Amercian Cancer Society estimates that over 20,000 women in the United States will be diagnosed with and over 13,000 women will die from ovarian cancer this year. High-grade serous ovarian carcinoma (HGSC)…
Prognostic and predictive blood-based biomarkers for pancreatic cancer
Value Proposition Pancreatic cancer is among the deadliest types of cancer, with only 8.2% of patients surviving five years after diagnosis. Therapeutics that inhibit either VEGF signaling pathways or mitogenic signaling through the epidermal growth…
Components of the Wnt-Beta-catenin paracrine signaling pathway as predictive biomarkers for cancer immunotherapy
Value Proposition Immunotherapy is a promising approach for the treatment of many cancers. However, despite early success, majority of patients with advanced cancer fail to respond or become resistant. In even the most immunogenic cancer…